Page last updated: 2024-08-25

clarithromycin and E coli Infections

clarithromycin has been researched along with E coli Infections in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (12.50)	18.2507
2000's	5 (62.50)	29.6817
2010's	1 (12.50)	24.3611
2020's	1 (12.50)	2.80

Authors

Authors	Studies
Castelletti, S; Cirioni, O; Ghiselli, R; Giacometti, A; Kamysz, E; Kamysz, W; Orlando, F; Riva, A; Rocchi, M; Saba, V; Scalise, G; Silvestri, C	1
Huang, E; Kaufmann, Y; Moon, SH	1
de Souza Carvalho-Wodarz, C; Dimer, F; Hartmann, R; Haupenthal, J; Lehr, CM	1
Bosnjak, B; Eraković Haber, V; Glojnarić, I; Hrvacić, B; Kramarić, MD; Pasalić, I; Situm, K; Tkalcević, VI	1
De Schepper, J; De Schutter, I; De Wachter, E; Malfroot, A; Vanbesien, J	1
Antonopoulou, A; Baziaka, F; Giamarellos-Bourboulis, EJ; Giamarellou, H; Kousoulas, V; Koutoukas, P; Panagou, C; Perrea, D; Sabracos, L	1
Adamis, T; Baziaka, F; Giamarellos-Bourboulis, E; Giamarellou, H; Karayannacos, P; Koutoukas, P; Plachouras, D; Raftogiannis, M; Sabracos, L; Tsaganos, T	1
Müller, O	1

Trials

1 trial(s) available for clarithromycin and E coli Infections

Article	Year
Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections. The Journal of antimicrobial chemotherapy, 1993, Volume: 31 Suppl E Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Azithromycin; Bacterial Infections; Child; Clarithromycin; Drug Administration Schedule; Erythromycin; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Otitis Media; Pharyngitis; Respiratory Tract Infections; Sinusitis; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pyogenes; Tonsillitis	1993

Article

Year

Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections.

The Journal of antimicrobial chemotherapy, 1993, Volume: 31 Suppl E

Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Azithromycin; Bacterial Infections; Child; Clarithromycin; Drug Administration Schedule; Erythromycin; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Otitis Media; Pharyngitis; Respiratory Tract Infections; Sinusitis; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pyogenes; Tonsillitis

1993

Other Studies

7 other study(ies) available for clarithromycin and E coli Infections

Article	Year
Efficacy of the combination of tachyplesin III and clarithromycin in rat models of Escherichia coli sepsis. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:12 Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Clarithromycin; Disease Models, Animal; DNA-Binding Proteins; Drug Therapy, Combination; Endotoxins; Escherichia coli; Escherichia coli Infections; Humans; Male; Peptides, Cyclic; Rats; Rats, Wistar; Sepsis; Treatment Outcome; Tumor Necrosis Factor-alpha	2008
Paenipeptin Analogues Potentiate Clarithromycin and Rifampin against Antimicrobial agents and chemotherapy, 2020, 03-24, Volume: 64, Issue:4 Topics: Animals; Bacterial Outer Membrane; Clarithromycin; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Mice; Polymyxins; Rifampin	2020
Inhalable Clarithromycin Microparticles for Treatment of Respiratory Infections. Pharmaceutical research, 2015, Volume: 32, Issue:12 Topics: Administration, Inhalation; Anti-Bacterial Agents; Cell Line; Clarithromycin; Dry Powder Inhalers; Escherichia coli; Escherichia coli Infections; Humans; Particle Size; Respiratory Tract Infections; Solubility; Staphylococcal Infections; Staphylococcus aureus	2015
The anti-inflammatory activity of clarithromycin inhibits TNFalpha production and prolongs survival following lipopolysaccharide administration in mice. International journal of antimicrobial agents, 2008, Volume: 32, Issue:2 Topics: Animals; Anti-Inflammatory Agents; Clarithromycin; Disease Models, Animal; Escherichia coli; Escherichia coli Infections; Humans; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Shock, Septic; Treatment Outcome; Tumor Necrosis Factor-alpha	2008
Inhaled budesonide induced Cushing's syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2003, Volume: 2, Issue:2 Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antifungal Agents; Aspergillosis, Allergic Bronchopulmonary; Aspergillus fumigatus; Bronchodilator Agents; Budesonide; Clarithromycin; Cushing Syndrome; Cystic Fibrosis; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Synergism; Drug Therapy, Combination; Escherichia coli Infections; Fatal Outcome; Female; Humans; Iatrogenic Disease; Infant, Newborn; Itraconazole; Lung Diseases; Male; Mycobacterium Infections, Nontuberculous	2003
Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis with Escherichia coli. International journal of antimicrobial agents, 2005, Volume: 25, Issue:2 Topics: Acute Disease; Amikacin; Animals; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Female; Humans; Inflammation; Lipopolysaccharides; Malondialdehyde; Pyelonephritis; Rabbits; Sepsis; Treatment Outcome; Tumor Necrosis Factor-alpha	2005
Clarithromycin: immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli. Scandinavian journal of infectious diseases, 2005, Volume: 37, Issue:1 Topics: Acute Disease; Amikacin; Animals; Anti-Bacterial Agents; Caspase 3; Caspases; Clarithromycin; Colony Count, Microbial; Escherichia coli; Escherichia coli Infections; Immunologic Factors; Male; Malondialdehyde; Pulmonary Edema; Pyelonephritis; Rabbits; Sepsis; Tumor Necrosis Factor-alpha	2005